Slideshow

Antipsychotic Augmentation vs Monotherapy in Schizophrenia

Author(s):

Brian Miller, MD, PhD, MPH

To augment or not to augment? That is the question.

View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.

Related Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
brain depression
nicotine use
brain schizophrenia
brain
schizophrenia
Related Content
FDA Committees Vote to Dismiss Clozapine REMS
November 20th 2024

FDA Committees Vote to Dismiss Clozapine REMS

Heidi Anne Duerr, MPH
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
schizophrenia
November 18th 2024

Long-Acting Injectables and a Team-Driven Approach for Schizophrenia Treatment

Tracy Hicks, DNP, FNP/PMHNP-BC
Blue Light Blockers: A Behavior Therapy for Mania
October 7th 2021

Blue Light Blockers: A Behavior Therapy for Mania

Chris Aiken, MD Kellie Newsome, PMH-NP
brain electric
November 12th 2024

Newly FDA-Cleared TMS for Major Depressive Disorder, Obsessive-Compulsive Disorder, and Anxious Depression

Leah Kuntz
trauma
November 12th 2024

Opening Pandora’s Box: The Importance of Assessing and Treating Trauma in Individuals Experiencing Psychosis

Sripriya Chari, PhD Grace Eun Lee, PhD Nichole D. Olson, PhD Kate V. Hardy, PsyD
© 2024 MJH Life Sciences

All rights reserved.